Zero ad trackers.We never sell your data.

Help paying for Wild-Type ATTR Cardiac Amyloidosis treatment

We found 3 drugmaker programs for Wild-Type ATTR Cardiac Amyloidosis medicines and 6 charity funds (1 open at our last check). Tell us your insurance below and we'll show what to try first.

Find what fits meCharity fundsDrugmaker programs
A caregiver in green scrubs leaning toward an older womanPhoto: Age Cymru / Unsplash

What to try first, depending on your insurance

Help for Wild-Type ATTR Cardiac Amyloidosis depends mostly on how you're covered. Pick the one that sounds like you. We'll name the funds and programs that fit, and what won't work, so you don't waste a phone call.

I have insurance through work or a plan I bought

3 funds and programs name private insurance
  • Taking Amvuttra? Ask Alnylam Assist about its copay card, which can lower what you pay each fill.
  • Taking Attruby? Ask ForgingBridges about its copay card, which can lower what you pay each fill.
  • You'll find 1 more drugmaker program for you further down this page.
  • One fund for Wild-Type ATTR Cardiac Amyloidosis is only for people with government coverage such as Medicare, so it won't take private insurance.

I'm on Medicare

3 funds and programs name Medicare
  • Apply to the Amyloidosis fund at TotalAssist. It was open on Oct 19 and pays up to $5,500 a year.
  • Taking Vyndamax? VynAssist / VyndaLink may give it to you free if you qualify, usually based on income.
  • Taking Amvuttra? Alnylam Assist offers insurance and case manager help to people with Medicare.
  • Drugmaker copay cards can't be used with Medicare. Federal rules bar them.
  • Medicare Part D caps what you pay for covered drugs at $2,100 a year in 2026.

Medicaid or CHIP covers me or my child

3 funds and programs name Medicaid
  • Apply to the Amyloidosis fund at TotalAssist. It was open on Oct 19 and pays up to $5,500 a year.
  • Taking Vyndamax? VynAssist / VyndaLink may give it to you free if you qualify, usually based on income.
  • Taking Amvuttra? Alnylam Assist offers insurance and case manager help to people with Medicaid.
  • Drugmaker copay cards can't be used with Medicaid or CHIP. Federal rules bar them.
  • Federal rules keep Medicaid copays for medicine low, so most help here is with getting a prescription approved. The drugmaker's support line can help your doctor with that paperwork.

I have TRICARE or get care through the VA

3 funds and programs name TRICARE or VA
  • Apply to the Amyloidosis fund at TotalAssist. It was open on Oct 19 and pays up to $5,500 a year.
  • Taking Vyndamax? VynAssist / VyndaLink may give it to you free if you qualify, usually based on income.
  • Taking Amvuttra? Alnylam Assist offers insurance and case manager help to people with TRICARE or VA coverage.
  • Drugmaker copay cards can't be used with TRICARE or the VA. Federal rules bar them.

I don't have insurance right now

3 funds and programs name people without insurance
  • Taking Amvuttra? Alnylam Assist may give it to you free if you qualify, usually based on income.
  • Taking Attruby? ForgingBridges may give it to you free if you qualify, usually based on income.
  • You'll find 1 more drugmaker program for you further down this page.
  • Charity funds pay copays and premiums, so nearly all of them need you to have some insurance.
  • Drugmaker support lines, such as Alnylam Assist at 1-833-256-2748, can check whether you qualify for coverage you don't have yet.

Charity funds for Wild-Type ATTR Cardiac Amyloidosis

Independent foundations pay copays, coinsurance and sometimes insurance premiums for people who already have coverage. Funds open and close as donations come in, so each one shows what the foundation said on the date we checked.

Open now1
Taking new applicants when we checked
TotalAssist

Amyloidosis fund

Covers: Out-of-pocket costs for approved medications. Up to $5,500 a year.

Requires Medicare, Medicaid or TRICARE
Apply on the foundation's siteChecked October 19, 2026
Waitlist or ask3
Join the list or ask the fund
NORD RareCare

Amyloidosis Medical Assistance fund

Covers: Medical and medication costs.

“Temporarily Waitlisting”
See the fund's pageChecked October 19, 2026
NORD RareCare

Amyloidosis Premium Copay Assistance fund

Covers: Insurance premiums and copays.

“Temporarily Waitlisting”
See the fund's pageChecked October 19, 2026
The Assistance Fund

Amyloidosis fund

Covers: Copays, coinsurance, deductibles and other health-related expenses.

“WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this…”
See the fund's pageChecked October 19, 2026
Closed for now2
Sign up to hear when it reopens
HealthWell Foundation

Amyloidosis fund

Covers: Copays, premiums or other treatment costs.

Get the reopening alertChecked October 19, 2026
HealthWell Foundation

Cardiomyopathy (Medicare Access) fund

Covers: Copays, premiums or other treatment costs.

Medicare patients only
Get the reopening alertChecked October 19, 2026

Help from the companies that make Wild-Type ATTR Cardiac Amyloidosis medicines

Copay cards lower what people with private insurance pay. Federal rules bar them for Medicare, Medicaid and TRICARE. Free medicine programs are for people without enough coverage and usually have income limits. We read each program on the drugmaker's own site.

AmvuttraVutrisiran

Support program: Alnylam Assist
Copay helpBridge or quick-start supplyFree medicine programInsurance and case manager help
What each one covers and who qualifies
  • Copay help

    The Alnylam Assist Copay Program covers certain out-of-pocket costs for eligible commercially insured patients. Not for Medicare, Medicaid or other government insurance.

    For: Private insurance · source
  • Bridge or quick-start supply

    Programs may help if you have a delay or change in insurance coverage; a Case Manager checks eligibility after a Start Form.

    The drugmaker's page doesn't say who qualifies, so ask the program. · source
  • Free medicine program

    The Alnylam Assist Patient Assistance Program provides treatment at no cost for eligible patients, mainly those who are uninsured.

    For: No insurance · source
  • Insurance and case manager help

    After your doctor submits a Start Form, a Case Manager contacts you within 2 business days with a summary of your insurance benefits.

    For: Private insurance, Medicare, Medicaid, TRICARE or VA, No insurance, underinsured · source

Most services start when your doctor submits the Alnylam Assist Start Form. Alnylam can also point uninsured or underinsured patients to independent foundations.

Read on the drugmaker's site September 24, 2026. Programs change, so confirm before you rely on it.

AttrubyAcoramidis

Support program: ForgingBridges
Copay helpFree medicine programBridge or quick-start supplyInsurance and case manager help
What each one covers and who qualifies
  • Copay help

    ForgingBridges Copay Assistance Program may lower out-of-pocket cost for Attruby to as little as $0 per month for eligible commercially insured patients.

    For: Private insurance · source
  • Free medicine program

    ForgingBridges Patient Assistance Program may provide Attruby free. Income criteria apply; must be uninsured, have limited coverage, or have an appeal denial.

    For: No insurance, underinsured · source
  • Bridge or quick-start supply

    ForgingBridges QuickStart Program may provide Attruby free for a short time during an insurance delay, if eligible.

    The drugmaker's page doesn't say who qualifies, so ask the program. · source
  • Insurance and case manager help

    A Patient Access Liaison (PAL) helps connect patients to financial support, including referrals to independent charitable foundations.

    The drugmaker's page doesn't say who qualifies, so ask the program. · source

ForgingBridges is BridgeBio's support program. Eligibility criteria and terms apply to all programs.

Read on the drugmaker's site September 24, 2026. Programs change, so confirm before you rely on it.

VyndamaxTafamidis

Support program: VynAssist / VyndaLink
Copay helpFree medicine programInsurance and case manager help
What each one covers and who qualifies
  • Copay help

    Co-Pay Savings Program: eligible commercially insured patients may pay as little as $0 per month; $10,000-$60,000 maximum benefit per calendar year.

    For: Private insurance · source
  • Free medicine program

    Pfizer Patient Assistance Program through VyndaLink may help eligible uninsured or government-insured patients when other options aren't available.

    For: No insurance, Medicare, Medicaid, TRICARE or VA · source
  • Insurance and case manager help

    A VynAssist Access Care Manager helps patients and caregivers understand coverage and financial support options.

    The drugmaker's page doesn't say who qualifies, so ask the program. · source

Covers VYNDAMAX. Pfizer stopped supplying VYNDAQEL in the U.S. as of December 31, 2025; VyndaLink offerings still apply to patients prescribed VYNDAQEL. Copay card excludes Medicare, Medicaid, TRICARE, VA and other government programs; copay questions: 1-888-222-8475. Patients must apply to and be denied by other sources before the Pfizer PAP considers them.

Read on the drugmaker's site October 12, 2026. Programs change, so confirm before you rely on it.

Before you pick up the phone

Most of these programs start with one call, and having these ready makes it shorter. Tick them off as you go. Nothing here is saved or sent anywhere.

Call the drugmaker's support line first. Its case managers check your benefits and often fill out forms with your doctor. If a charity fund is closed, sign up on the foundation's page to hear when it reopens. Most programs need renewing every year, and many copay cards reset in January.

Questions people ask about paying for Wild-Type ATTR Cardiac Amyloidosis treatment

Is there financial help for Wild-Type ATTR Cardiac Amyloidosis treatment?

Yes. Trial Friend lists 3 drugmaker programs for Wild-Type ATTR Cardiac Amyloidosis medicines and 6 charity funds, 1 of them open at our last check. We checked every one at the source on or before October 19, 2026. Which ones fit depends on your insurance. Copay cards are for people with private insurance, charity funds usually need some insurance, and free medicine programs are for people without enough coverage.

Can I use a copay card for Wild-Type ATTR Cardiac Amyloidosis medicine if I have Medicare?

No. Federal rules bar drugmaker copay cards for drugs paid by Medicare, Medicaid or TRICARE. For Wild-Type ATTR Cardiac Amyloidosis, 1 charity fund on this page accepts Medicare (1 open at our last check), and 1 drugmaker free medicine program names Medicare patients among those who may qualify. In 2026, Medicare Part D also caps yearly out-of-pocket costs for covered drugs at $2,100.

Which Wild-Type ATTR Cardiac Amyloidosis charity funds are open right now?

At our last check, TotalAssist's Amyloidosis fund was open to new applicants. Funds open and close as donations come in, so check the foundation's page before you apply.

What help is there for Wild-Type ATTR Cardiac Amyloidosis treatment without insurance?

Of the drugmaker programs for Wild-Type ATTR Cardiac Amyloidosis medicines, 3 offer free medicine to people without insurance who qualify, usually with income limits. Most charity funds pay copays and premiums, so they need some insurance. The drugmaker's support line can also check whether you qualify for coverage you don't have yet.

Where to go next

Understand it
Wild-Type ATTR Cardiac Amyloidosis guide and clinical trials →
Nearby
Wild-Type ATTR Cardiac Amyloidosis trial sites near you →
Every condition
Help paying for all rare disease medicines →

How we check: drugmaker programs come only from each drugmaker's own pages. Fund status is copied from each foundation's list (TotalAssist, NORD RareCare, The Assistance Fund, HealthWell Foundation) on the date shown. Programs change, so confirm with the program before you rely on it. Trial Friend shares information, not financial, legal or medical advice, and each program decides who qualifies. See something wrong? Email jason@trialfriend.com.